JAK2 inhibition for the treatment of hematologic and solid malignancies

Brian L. Harry, S Gail Eckhardt, Antonio Jimeno

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Introduction: Mutations in Janus kinase 2 (JAK2), and in particular JAK2 V617F, are common in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In the past several years, JAK2 inhibitors have been rapidly developed as targeted therapies for MPNs. Areas covered: JAK2 mutations, including JAK2 V617F and unique fusion proteins, are critical for oncogenesis of some hematologic malignancies. Although JAK2 mutations are extremely rare in solid cancers, pathophysiological JAK2/STAT signaling can still promote tumor cell growth, proliferation, migration, invasion and angiogenesis. JAK2 inhibition can curtail malignant cellular behaviors and thus may be a promising therapeutic strategy. Expert opinion: The involvement of oncogenic JAK2 mutations in hematologic malignancies indicates that JAK2 inhibition has the potential to be a highly successful treatment option. The exact role of JAK2 signaling in solid cancers is unclear, but JAK2 inhibition may prevent disease progression by restricting malignant cell phenotypes. JAK2 inhibitors in development for the treatment of MPNs have demonstrated clinical activity with minimal toxicity. This class of agents should be investigated more rigorously for the treatment of other malignancies with aberrant JAK2 signaling with or without JAK2 mutations.

Original languageEnglish (US)
Pages (from-to)637-655
Number of pages19
JournalExpert Opinion on Investigational Drugs
Volume21
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Janus Kinase 2
Hematologic Neoplasms
Mutation
Neoplasms
Philadelphia Chromosome
Expert Testimony

Keywords

  • AG-490
  • AT-9283
  • AZ-960
  • AZD-1480
  • BMS-911543
  • CEP-701
  • CYT-387
  • Essential thrombocythemia
  • INCB-018424
  • Janus kinase 2 (JAK2)
  • Lestaurtinib
  • MK-0457
  • Myelofibrosis
  • Polycythemia vera
  • Ruxolitinib
  • SAR-302503
  • SB-1518
  • TG-101348
  • VX-680
  • WP-1066
  • XL-019

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

JAK2 inhibition for the treatment of hematologic and solid malignancies. / Harry, Brian L.; Eckhardt, S Gail; Jimeno, Antonio.

In: Expert Opinion on Investigational Drugs, Vol. 21, No. 5, 01.05.2012, p. 637-655.

Research output: Contribution to journalReview article

@article{2577e288490e40049769b9d0ee09edf0,
title = "JAK2 inhibition for the treatment of hematologic and solid malignancies",
abstract = "Introduction: Mutations in Janus kinase 2 (JAK2), and in particular JAK2 V617F, are common in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In the past several years, JAK2 inhibitors have been rapidly developed as targeted therapies for MPNs. Areas covered: JAK2 mutations, including JAK2 V617F and unique fusion proteins, are critical for oncogenesis of some hematologic malignancies. Although JAK2 mutations are extremely rare in solid cancers, pathophysiological JAK2/STAT signaling can still promote tumor cell growth, proliferation, migration, invasion and angiogenesis. JAK2 inhibition can curtail malignant cellular behaviors and thus may be a promising therapeutic strategy. Expert opinion: The involvement of oncogenic JAK2 mutations in hematologic malignancies indicates that JAK2 inhibition has the potential to be a highly successful treatment option. The exact role of JAK2 signaling in solid cancers is unclear, but JAK2 inhibition may prevent disease progression by restricting malignant cell phenotypes. JAK2 inhibitors in development for the treatment of MPNs have demonstrated clinical activity with minimal toxicity. This class of agents should be investigated more rigorously for the treatment of other malignancies with aberrant JAK2 signaling with or without JAK2 mutations.",
keywords = "AG-490, AT-9283, AZ-960, AZD-1480, BMS-911543, CEP-701, CYT-387, Essential thrombocythemia, INCB-018424, Janus kinase 2 (JAK2), Lestaurtinib, MK-0457, Myelofibrosis, Polycythemia vera, Ruxolitinib, SAR-302503, SB-1518, TG-101348, VX-680, WP-1066, XL-019",
author = "Harry, {Brian L.} and Eckhardt, {S Gail} and Antonio Jimeno",
year = "2012",
month = "5",
day = "1",
doi = "10.1517/13543784.2012.677432",
language = "English (US)",
volume = "21",
pages = "637--655",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - JAK2 inhibition for the treatment of hematologic and solid malignancies

AU - Harry, Brian L.

AU - Eckhardt, S Gail

AU - Jimeno, Antonio

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Introduction: Mutations in Janus kinase 2 (JAK2), and in particular JAK2 V617F, are common in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In the past several years, JAK2 inhibitors have been rapidly developed as targeted therapies for MPNs. Areas covered: JAK2 mutations, including JAK2 V617F and unique fusion proteins, are critical for oncogenesis of some hematologic malignancies. Although JAK2 mutations are extremely rare in solid cancers, pathophysiological JAK2/STAT signaling can still promote tumor cell growth, proliferation, migration, invasion and angiogenesis. JAK2 inhibition can curtail malignant cellular behaviors and thus may be a promising therapeutic strategy. Expert opinion: The involvement of oncogenic JAK2 mutations in hematologic malignancies indicates that JAK2 inhibition has the potential to be a highly successful treatment option. The exact role of JAK2 signaling in solid cancers is unclear, but JAK2 inhibition may prevent disease progression by restricting malignant cell phenotypes. JAK2 inhibitors in development for the treatment of MPNs have demonstrated clinical activity with minimal toxicity. This class of agents should be investigated more rigorously for the treatment of other malignancies with aberrant JAK2 signaling with or without JAK2 mutations.

AB - Introduction: Mutations in Janus kinase 2 (JAK2), and in particular JAK2 V617F, are common in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In the past several years, JAK2 inhibitors have been rapidly developed as targeted therapies for MPNs. Areas covered: JAK2 mutations, including JAK2 V617F and unique fusion proteins, are critical for oncogenesis of some hematologic malignancies. Although JAK2 mutations are extremely rare in solid cancers, pathophysiological JAK2/STAT signaling can still promote tumor cell growth, proliferation, migration, invasion and angiogenesis. JAK2 inhibition can curtail malignant cellular behaviors and thus may be a promising therapeutic strategy. Expert opinion: The involvement of oncogenic JAK2 mutations in hematologic malignancies indicates that JAK2 inhibition has the potential to be a highly successful treatment option. The exact role of JAK2 signaling in solid cancers is unclear, but JAK2 inhibition may prevent disease progression by restricting malignant cell phenotypes. JAK2 inhibitors in development for the treatment of MPNs have demonstrated clinical activity with minimal toxicity. This class of agents should be investigated more rigorously for the treatment of other malignancies with aberrant JAK2 signaling with or without JAK2 mutations.

KW - AG-490

KW - AT-9283

KW - AZ-960

KW - AZD-1480

KW - BMS-911543

KW - CEP-701

KW - CYT-387

KW - Essential thrombocythemia

KW - INCB-018424

KW - Janus kinase 2 (JAK2)

KW - Lestaurtinib

KW - MK-0457

KW - Myelofibrosis

KW - Polycythemia vera

KW - Ruxolitinib

KW - SAR-302503

KW - SB-1518

KW - TG-101348

KW - VX-680

KW - WP-1066

KW - XL-019

UR - http://www.scopus.com/inward/record.url?scp=84859721377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859721377&partnerID=8YFLogxK

U2 - 10.1517/13543784.2012.677432

DO - 10.1517/13543784.2012.677432

M3 - Review article

C2 - 22493978

AN - SCOPUS:84859721377

VL - 21

SP - 637

EP - 655

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -